Xeloda (zah-LOE-duh, capecitabine), the first ORAL drug for metastatic breast cancer
June 1998
Roche is now marketing Xeloda (zah-LOE-duh, capecitabine),the first ORAL drug for metastatic breast cancer.
It's for patients who can't take, or are resistant to, treatmentwith paclitaxel (Taxol) and anthracyclines (Adriamycin, etc).
Xeloda is a prodrug of 5-FU (5-fluorouracil). It'smetabolized to 5-FU by enzymes in tumor cells.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote